Abenovelab
The computed 12-month bankruptcy probability of Abenovelab is 0.2% (very low). The 2025 annual accounts show equity of €43k and a net result of €168k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 28% of 2209 sector peers (fiscal year 2025). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €43k |
| Net result | €168k |
| Better than sector | 28% |
| Active | 4 yrs |
Strong profile, led by profitability.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 19.3% | 58.2% | |
| Net result | €168k | €60k | |
| Equity | €43k | €74k | |
| Gross operating margin | €214k | €96k | |
| Total assets | €223k | €187k |
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | €214k |
| Net profit | €168k |
| Cash flow | €171k |
| Staff costs | - |
| Income taxes | €50k |
| Dividends | €533k |
| Total assets | €223k |
| Equity | €43k |
| Debt | €180k |
| of which ≤ 1y | €177k |
| of which > 1y | - |
| Working capital | €45k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 1.25 |
| Quick ratio | 1.25 |
| Working capital ratio | 20.0% |
| Solvency | 19.3% |
| Debt / equity | 4.17 |
| Long-term debt ratio | - |
| Interest coverage | 125.10 |
| Gross margin | - |
| Net margin | - |
| ROA | 75.6% |
| ROE | 390.9% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €223k |
| Fixed assets | 21/28 | €2k |
| Tangible fixed assets | 22/27 | €2k |
| Current assets | 29/58 | €221k |
| Amounts receivable within one year | 40/41 | €137k |
| Investments | 50/53 | €60k |
| Cash & bank | 54/58 | €24k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €223k |
| Equity | 10/15 | €43k |
| Contributions / capital | 10/11 | €1k |
| Reserves | 13 | €42k |
| Amounts payable | 17/49 | €180k |
| Amounts payable within one year | 42/48 | €177k |
| Trade debts payable within one year | 44 | €19 |
| Income statement | ||
| Gross operating margin | 9900 | €214k |
| Operating result | 9901 | €211k |
| Financial income | 75 | €9k |
| Financial charges | 65 | €2k |
| Result before taxes | 9903 | €218k |
| Income taxes | 67/77 | €50k |
| Net result for the period | 9904 | €168k |
| Result to be appropriated | 9905 | €168k |
| NACE primary | Human health(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 17-01-2022 |
| Status | Active |
| Postal code | 8670 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 38025B0349/00A002 | Flanders | 3.8 ha | 1 · 1.1 ha | - |
| 38014F0745/00A000 | Flanders | 704 m² | 1 · 120 m² | 7.1 m · 1 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
18-11-2025 Registered office moved from Evergem to Koksijde
- Dellaertsdreef 24, 9940 Evergem → Hostenstraat, 8670 Koksijde
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Koksijde",
"region": null,
"street": "Hostenstraat",
"country": "BE",
"postcode": "8670",
"box_number": null,
"street_number": null
},
"old_address": {
"city": "Evergem",
"region": null,
"street": "Dellaertsdreef",
"country": "BE",
"postcode": "9940",
"box_number": "A",
"street_number": "24"
},
"effective_date": "2025-11-07",
"evidence_quote": "TWEEDE BESLUIT \u2013 ADRES VAN DE ZETEL De vergadering besluit het adres van de zetel over te brengen naar 8670 Koksijde, Hostenstraat"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0780.558.109",
"name_full": "DR. TIM VAN DEN ABEELE - KLINISCHE BIOLOGIE",
"legal_form": "BV"
}
}04-10-2023 Registered office moved from Melle to Sleidinge
- Vossenstraat 122, 9090 Melle → Dellaertsdreef 24, 9940 Sleidinge
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Sleidinge",
"region": null,
"street": "Dellaertsdreef",
"country": "BE",
"postcode": "9940",
"box_number": "A",
"street_number": "24"
},
"old_address": {
"city": "Melle",
"region": null,
"street": "Vossenstraat",
"country": "BE",
"postcode": "9090",
"box_number": "a",
"street_number": "122"
},
"effective_date": "2023-07-14",
"evidence_quote": "Bij beslissing van de bestuurder dd 14/07/2023 wordt de maatschappelijke zetel vanaf 14 juli 2023 verplaatst van Vossenstraat 122 a, 9090 Melle naar Dellaertsdreef 24 A, 9940 Sleidinge"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0780.558.109",
"name_full": "DR. TIM VAN DEN ABEELE - KLINISCHE BIOLOGIE",
"legal_form": "BV"
}
}19-01-2022 Incorporation of a new BV
Technical details
{
"kind": "oprichting",
"seat": "9090 Melle, Vossenstraat 122a",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1984-05-17",
"name": "Van den Abeele Tim Marc Julie",
"niss": null,
"address": "9090 Melle, Vossenstraat 122 A"
},
"share_class": "naam",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 1000,
"holder_person_name": "Van den Abeele Tim Marc Julie",
"is_subscriber_only": false,
"n_shares_subscribed": 50,
"amount_subscribed_eur": 1000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 1000,
"subject_company": {
"kbo": "0780.558.109",
"name_full": "Dr. Tim Van den Abeele \u2013 Klinische biologie",
"legal_form": "BV"
},
"initial_directors": [],
"incorporation_date": "2022-01-17",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | Abenovelab |